The U.S. Food and Drug Administration approved GSK’s depemokimab (brand name Exdensur) as an add‑on maintenance therapy for patients aged 12 and older with severe eosinophilic asthma. The approval is supported by two late‑stage SWIFT trials showing reductions in asthma attacks and hospitalizations versus placebo. GSK emphasized the drug’s twice‑yearly dosing schedule as a competitive adherence advantage against existing biologics. Regulators and company data cite meaningful reductions in exacerbations in SWIFT‑1 and SWIFT‑2; the European CHMP recommended the drug across related indications earlier this year. IL‑5 is a cytokine that promotes eosinophil survival and is a validated target in type‑2 inflammatory asthma — blocking it reduces eosinophil‑driven exacerbations. Clinicians will watch real‑world uptake and payer coverage given the crowded biologics market for severe asthma.